acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission#628578ClinicalTrials.gov
• A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations#908942ClinicalTrials.gov
• Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia#871638ClinicalTrials.gov
• DC Vaccination for Post-remission Therapy in AML#387142ClinicalTrials.gov
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission#994058ClinicalTrials.gov
• Tipifarnib in Treating Young Patients With Refractory Leukemia#861791ClinicalTrials.gov
• BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia#861744ClinicalTrials.gov
• CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies#879184ClinicalTrials.gov
• Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study#367161Gestión del Repositorio Documental de la Universidad de Salamanca
• Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia#367163Gestión del Repositorio Documental de la Universidad de Salamanca
• A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review#812419ClinicalTrials.gov
• Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia#861875ClinicalTrials.gov
• Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting#872925ClinicalTrials.gov
• Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia#888603ClinicalTrials.gov
• 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia#918886ClinicalTrials.gov
• AN RNA-INTERACTION DOMAIN SCREEN IDENTIFIES PTBP1 AS A DEPENDENCY IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA#929117ScholarlyCommons
• Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia#832680ClinicalTrials.gov
• Prevention of Oral Mucositis in Adults in With Hematologic Malignancy#831220ClinicalTrials.gov
• A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors#1008162ClinicalTrials.gov
• Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer#802899ClinicalTrials.gov
• Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia#872043ClinicalTrials.gov
• Personalized NK Cell Therapy in CBT#800851ClinicalTrials.gov
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies#913895ClinicalTrials.gov
• PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)#911518ClinicalTrials.gov
• Integrated analyses of large scale RNA-seq data in acute myeloid leukemia#370805HAL (France)
• T-Cell miR-155 Regulates the Response to Tumor-Specific mRNA Vaccines in a Murine Model of Acute Myeloid Leukemia#656597İzmir Yüksek Teknoloji Enstitüsü
• A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy#847026ClinicalTrials.gov
• Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT#873698ClinicalTrials.gov
• Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML#886957ClinicalTrials.gov
• T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)#980702ClinicalTrials.gov
• Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia#850526ClinicalTrials.gov
• Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia#888811ClinicalTrials.gov
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant#896797ClinicalTrials.gov
• Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML#825605ClinicalTrials.gov
• A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia#982472ClinicalTrials.gov
• Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML#889362ClinicalTrials.gov
• Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant#127609ClinicalTrials.gov
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies#869700ClinicalTrials.gov
• A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML#850661ClinicalTrials.gov
• Metabolism Des LAM#878309ClinicalTrials.gov
• NGS in AML Relapse#994300ClinicalTrials.gov
• Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients#1032079ClinicalTrials.gov
• Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study#147559HAL (France)
• Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission#811504ClinicalTrials.gov
• Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay#826153ClinicalTrials.gov
• A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations#841227ClinicalTrials.gov
• Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML#850185ClinicalTrials.gov
• Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation#811961ClinicalTrials.gov
• Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain#837586ClinicalTrials.gov
• Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia#865549ClinicalTrials.gov